These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24290927)

  • 21. Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio.
    Marcu LG; Bezak E
    J Theor Biol; 2012 Mar; 297():41-7. PubMed ID: 22182756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential innovations in scheduling of cancer chemotherapy.
    Norton L; Day R
    Important Adv Oncol; 1991; ():57-72. PubMed ID: 1869282
    [No Abstract]   [Full Text] [Related]  

  • 25. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug stability and compatibility in oncology care.
    Williams DA
    J Infus Chemother; 1996; 6(4):195-202. PubMed ID: 9229315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction chemotherapy as initial treatment for advanced head and neck cancer: a model for the multidisciplinary treatment of solid tumors.
    Clark JR; Fallon BG; Frei E
    Important Adv Oncol; 1987; ():175-95. PubMed ID: 3331380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal dosing of cancer chemotherapy using model predictive control and moving horizon state/parameter estimation.
    Chen T; Kirkby NF; Jena R
    Comput Methods Programs Biomed; 2012 Dec; 108(3):973-83. PubMed ID: 22739208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
    Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
    Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
    Conley BA; Forrest A; Egorin MJ; Zuhowski EG; Sinibaldi V; Van Echo DA
    Cancer Res; 1989 Jun; 49(12):3436-40. PubMed ID: 2720696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Planning and tracking chemotherapy production for cancer treatment: a performing and integrated solution.
    Kergosien Y; Tournamille JF; Laurence B; Billaut JC
    Int J Med Inform; 2011 Sep; 80(9):655-62. PubMed ID: 21778104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized drug administration for cancer treatment using Model Reference Adaptive Control.
    Babaei N; Salamci MU
    J Theor Biol; 2015 Apr; 371():24-44. PubMed ID: 25665717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronopharmacology and chronotherapy of cancers].
    Lévi F
    Pathol Biol (Paris); 1996 Sep; 44(7):631-44. PubMed ID: 8977920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints.
    Mukherjee A; Majumder D
    Biosystems; 2008 Jan; 91(1):108-16. PubMed ID: 17889991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and computer-aided design of chemotherapy plans.
    Hammond P; Modgil S; Wyatt JC
    Top Health Inf Manage; 2000 May; 20(4):55-66. PubMed ID: 10977142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1997 Dec; 14(4):283-303. PubMed ID: 9415996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relieving nausea and vomiting in patients with cancer: a treatment algorithm.
    Johnson MH; Moroney CE; Gay CF
    Oncol Nurs Forum; 1997; 24(1):51-7. PubMed ID: 9007907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.